PGEN
Precigen, Inc.
Price Chart
Latest Quote
$5.25
+0.43 (+9.02%)
Current Price
| Previous Close | $4.82 |
| Open | $4.90 |
| Day High | $5.34 |
| Day Low | $4.89 |
| Volume | 5,649,329 |
Stock Information
| Shares Outstanding | 356.51M |
| Total Debt | $98.25M |
| Cash Equivalents | $56.25M |
| Revenue | $31.59M |
| Net Income | $-383.42M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.87B |
| EPS (TTM) | $-1.21 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.76B |
| Sales | $31.59M |
| Income | $-383.42M |
| Book/sh | $0.06 |
| Cash/sh | $0.16 |
| Employees | 160 |
Financial Ratios
| Quick Ratio | 3.93 |
| Current Ratio | 4.82 |
| Debt/Eq | 485.55 |
Returns & Margins
| ROA | -42.07% |
| ROE | -1145.42% |
| Gross Margin | -35.38% |
| Operating Margin | -25.78% |
Ownership
| Insider Ownership | 13.71% |
| Institutional Ownership | 71.14% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -23.89 |
| P/S | 59.30 |
| P/B | 92.19 |
Analyst Data
| Recommendation | buy |
| Target Price | $12.45 |
Technical Indicators
| SMA20 | $4.27 |
| SMA50 | $4.19 |
| SMA200 | $4.03 |
| RSI | 71.54 |
| ATR | 0.3100 |
| Shares Float | 189.46M |
| Short Float | 20.79% |
| Short Ratio | 10.57 |
| Volatility | 1.06 |
| Rel Volume | 1.05 |
Performance History
| Week | +18.09% |
| Month | +23.07% |
| Quarter | +60.21% |
| 6 Months | +32.04% |
| YTD | +22.78% |
| Year | +252.68% |
| 3 Years | +323.79% |
| 5 Years | -25.46% |
| 10 Years | -78.49% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $5.26 | 5,649,329 |
| 2026-06-18 | $4.82 | 4,755,600 |
| 2026-06-17 | $4.73 | 3,834,300 |
| 2026-06-16 | $4.75 | 3,576,800 |
| 2026-06-15 | $4.80 | 6,770,900 |
| 2026-06-12 | $4.45 | 4,552,000 |
| 2026-06-11 | $4.53 | 9,956,300 |
| 2026-06-10 | $3.89 | 4,243,900 |
| 2026-06-09 | $3.71 | 3,545,700 |
| 2026-06-08 | $3.57 | 4,631,200 |
| 2026-06-05 | $3.58 | 5,330,700 |
| 2026-06-04 | $3.86 | 4,089,900 |
| 2026-06-03 | $3.81 | 7,793,900 |
| 2026-06-02 | $3.86 | 9,639,300 |
| 2026-06-01 | $4.12 | 4,835,700 |
| 2026-05-29 | $4.34 | 5,544,100 |
| 2026-05-28 | $4.51 | 5,690,600 |
| 2026-05-27 | $4.40 | 5,748,700 |
| 2026-05-26 | $4.24 | 6,098,100 |
| 2026-05-22 | $4.24 | 1,712,900 |
About Precigen, Inc.
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ÂŊ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
đ° Latest News
Precigen (PGEN) Secures FDA Orphan Drug Exclusivity for PAPZIMEOS
Insider Monkey âĸ 2026-06-20T17:28:27Z
H.C. Wainwright Remains a Buy on Precigen (PGEN)
Insider Monkey âĸ 2026-06-16T18:45:45Z
Precigen (PGEN) Stock Valuation Check As High P/B Multiple Meets Large DCF Upside Estimate
Simply Wall St. âĸ 2026-06-14T16:11:51Z
Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?
Motley Fool âĸ 2026-06-12T20:05:05Z
Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?
Zacks âĸ 2026-06-01T16:00:02Z
Spotlight On 3 Growth Companies With Strong Insider Stakes
Simply Wall St. âĸ 2026-05-26T17:36:03Z
Precigen (PGEN): The Best Penny Stock to Buy for Long Term
Insider Monkey âĸ 2026-05-22T18:41:30Z
Earnings Beat: Precigen, Inc. (NASDAQ:PGEN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Simply Wall St. âĸ 2026-05-16T12:32:42Z
3 Growth Companies With High Insider Ownership And Up To 71% Earnings Growth
Simply Wall St. âĸ 2026-05-14T17:36:05Z
Precigen, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-14T12:30:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $4,823,000 | $4,267,000 | $6,119,000 | $6,339,000 |
| Cost Of Revenue | $4,823,000 | $4,267,000 | $6,119,000 | $6,339,000 |
| Total Revenue | $9,684,000 | $3,925,000 | $6,225,000 | $26,909,000 |
| Operating Revenue | $9,684,000 | $3,925,000 | $6,225,000 | $26,658,000 |
| Expenses | ||||
| Interest Expense | $3,867,000 | $6,000 | $468,000 | $6,774,000 |
| Total Expenses | $116,284,000 | $98,630,000 | $95,148,000 | $101,515,000 |
| Other Income Expense | $-143,387,000 | $-34,735,000 | $-10,208,000 | $1,281,000 |
| Other Non Operating Income Expenses | $43,000 | $5,589,000 | $627,000 | $1,539,000 |
| Net Non Operating Interest Income Expense | $-652,000 | $1,412,000 | $2,769,000 | $-6,641,000 |
| Interest Expense Non Operating | $3,867,000 | $6,000 | $468,000 | $6,774,000 |
| Operating Expense | $111,461,000 | $94,363,000 | $89,029,000 | $95,176,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-250,642,000 | $-126,235,000 | $-95,904,000 | $-79,777,000 |
| Net Interest Income | $-652,000 | $1,412,000 | $2,769,000 | $-6,641,000 |
| Interest Income | $3,215,000 | $1,418,000 | $3,237,000 | $133,000 |
| Normalized Income | $-107,212,000 | $-86,475,536 | $-85,123,175 | $-78,659,647 |
| Net Income From Continuing And Discontinued Operation | $-250,642,000 | $-126,235,000 | $-95,904,000 | $28,317,000 |
| Total Operating Income As Reported | $-110,507,000 | $-135,029,000 | $-99,758,000 | $-75,726,000 |
| Net Income Common Stockholders | $-429,642,000 | $-126,235,000 | $-95,904,000 | $28,317,000 |
| Net Income | $-250,642,000 | $-126,235,000 | $-95,904,000 | $28,317,000 |
| Net Income Including Noncontrolling Interests | $-250,642,000 | $-126,235,000 | $-95,904,000 | $28,317,000 |
| Net Income Continuous Operations | $-250,642,000 | $-126,235,000 | $-95,904,000 | $-79,777,000 |
| Pretax Income | $-250,639,000 | $-128,028,000 | $-96,362,000 | $-79,966,000 |
| Special Income Charges | $-3,907,000 | $-40,324,000 | $-10,835,000 | $-1,120,000 |
| Interest Income Non Operating | $3,215,000 | $1,418,000 | $3,237,000 | $133,000 |
| Operating Income | $-106,600,000 | $-94,705,000 | $-88,923,000 | $-74,606,000 |
| Gross Profit | $4,861,000 | $-342,000 | $106,000 | $20,570,000 |
| Net Income Discontinuous Operations | - | $0 | $0 | $108,094,000 |
| Earnings From Equity Interest | - | $0 | $0 | $862,000 |
| Per Share | ||||
| Diluted EPS | $-1.37 | $-0.47 | $-0.39 | $0.14 |
| Basic EPS | $-1.37 | $-0.47 | $-0.39 | $0.14 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $-564,536 | $-54,175 | $-2,647 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-100,143,000 | $-83,172,000 | $-78,391,000 | $-61,307,000 |
| Total Unusual Items | $-143,430,000 | $-40,324,000 | $-10,835,000 | $-1,120,000 |
| Total Unusual Items Excluding Goodwill | $-143,430,000 | $-40,324,000 | $-10,835,000 | $-1,120,000 |
| Reconciled Depreciation | $3,199,000 | $4,526,000 | $6,668,000 | $10,765,000 |
| EBITDA (Bullshit earnings) | $-243,573,000 | $-123,496,000 | $-89,226,000 | $-62,427,000 |
| EBIT | $-246,772,000 | $-128,022,000 | $-95,894,000 | $-73,192,000 |
| Diluted Average Shares | $312,980,562 | $267,727,426 | $244,536,221 | $200,360,821 |
| Basic Average Shares | $312,980,562 | $267,727,426 | $244,536,221 | $200,360,821 |
| Diluted NI Availto Com Stockholders | $-429,642,000 | $-126,235,000 | $-95,904,000 | $28,317,000 |
| Preferred Stock Dividends | $179,000,000 | - | - | - |
| Tax Provision | $3,000 | $-1,793,000 | $-458,000 | $-189,000 |
| Impairment Of Capital Assets | $3,907,000 | $40,324,000 | $10,835,000 | $1,120,000 |
| Gain On Sale Of Security | $-139,523,000 | - | - | - |
| Research And Development | $41,333,000 | $53,070,000 | $48,614,000 | $47,170,000 |
| Selling General And Administration | $70,128,000 | $41,293,000 | $40,415,000 | $48,006,000 |
| Minority Interests | - | - | - | - |
| Write Off | - | - | - | - |
| Restructuring And Mergern Acquisition | - | - | - | - |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $2,497,000 | $14,919,000 | $51,185,000 | $44,881,000 |
| Total Assets | $155,505,000 | $145,266,000 | $151,043,000 | $215,977,000 |
| Total Non Current Assets | $40,270,000 | $42,852,000 | $82,288,000 | $97,818,000 |
| Other Non Current Assets | $982,000 | $459,000 | $846,000 | $1,148,000 |
| Investmentin Financial Assets | $2,511,000 | $0 | - | $0 |
| Goodwill And Other Intangible Assets | $18,414,000 | $23,594,000 | $67,313,000 | $81,378,000 |
| Other Intangible Assets | $3,182,000 | $4,455,000 | $40,701,000 | $44,455,000 |
| Current Assets | $115,235,000 | $102,414,000 | $68,755,000 | $118,159,000 |
| Other Current Assets | $3,434,000 | $3,341,000 | $4,325,000 | $5,066,000 |
| Inventory | $9,581,000 | $0 | - | $287,000 |
| Receivables | $4,362,000 | $1,163,000 | $1,575,000 | $13,804,000 |
| Other Receivables | $446,000 | $237,000 | $673,000 | $12,826,000 |
| Accounts Receivable | $3,916,000 | $926,000 | $902,000 | $978,000 |
| Allowance For Doubtful Accounts Receivable | $0 | $0 | $-184,000 | $-184,000 |
| Gross Accounts Receivable | $3,916,000 | $926,000 | $1,086,000 | $1,162,000 |
| Cash Cash Equivalents And Short Term Investments | $97,858,000 | $97,910,000 | $62,855,000 | $55,950,000 |
| Cash And Cash Equivalents | $30,234,000 | $29,517,000 | $7,578,000 | $4,858,000 |
| Restricted Cash | - | - | $0 | $43,339,000 |
| Assets Held For Sale Current | - | - | - | $0 |
| Prepaid Assets | - | - | - | - |
| Notes Receivable | - | - | - | - |
| Debt | ||||
| Net Debt | $62,940,000 | - | - | $38,361,000 |
| Total Debt | $98,290,000 | $5,502,000 | $7,097,000 | $51,420,000 |
| Long Term Debt And Capital Lease Obligation | $97,154,000 | $4,546,000 | $5,895,000 | $6,992,000 |
| Long Term Debt | $93,174,000 | - | - | - |
| Current Debt And Capital Lease Obligation | $1,136,000 | $956,000 | $1,202,000 | $44,428,000 |
| Current Debt | - | - | - | $43,219,000 |
| Other Current Borrowings | - | - | - | $43,219,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $134,594,000 | $106,753,000 | $32,545,000 | $89,718,000 |
| Total Non Current Liabilities Net Minority Interest | $97,288,000 | $85,235,000 | $9,560,000 | $11,073,000 |
| Other Non Current Liabilities | $134,000 | - | - | - |
| Derivative Product Liabilities | $0 | $50,537,000 | $0 | - |
| Non Current Deferred Liabilities | $0 | $1,934,000 | $3,665,000 | $4,081,000 |
| Current Liabilities | $37,306,000 | $21,518,000 | $22,985,000 | $78,645,000 |
| Current Deferred Liabilities | $517,000 | $589,000 | $509,000 | $25,000 |
| Payables And Accrued Expenses | $25,454,000 | $11,556,000 | $13,024,000 | $27,815,000 |
| Payables | $11,985,000 | $3,531,000 | $1,726,000 | $4,068,000 |
| Accounts Payable | $11,985,000 | $3,531,000 | $1,726,000 | $4,068,000 |
| Non Current Deferred Taxes Liabilities | - | $0 | $1,847,000 | $2,263,000 |
| Liabilities Heldfor Sale Non Current | - | - | - | $0 |
| Other Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $20,911,000 | $38,513,000 | $118,498,000 | $126,259,000 |
| Total Equity Gross Minority Interest | $20,911,000 | $38,513,000 | $118,498,000 | $126,259,000 |
| Stockholders Equity | $20,911,000 | $38,513,000 | $118,498,000 | $126,259,000 |
| Gains Losses Not Affecting Retained Earnings | $7,000 | $12,000 | $-1,947,000 | $-3,488,000 |
| Other Equity Adjustments | $7,000 | $12,000 | $-1,947,000 | $-3,488,000 |
| Retained Earnings | $-2,341,348,000 | $-2,090,706,000 | $-1,964,471,000 | $-1,868,567,000 |
| Preferred Securities Outside Stock Equity | $0 | $28,218,000 | $0 | - |
| Other | ||||
| Ordinary Shares Number | $353,910,926 | $292,869,097 | $248,919,096 | $208,150,021 |
| Share Issued | $353,910,926 | $292,869,097 | $256,398,527 | $208,150,021 |
| Tangible Book Value | $2,497,000 | $14,919,000 | $51,185,000 | $44,881,000 |
| Invested Capital | $114,085,000 | $38,513,000 | $118,498,000 | $169,478,000 |
| Working Capital | $77,929,000 | $80,896,000 | $45,770,000 | $39,514,000 |
| Capital Lease Obligations | $5,116,000 | $5,502,000 | $7,097,000 | $8,201,000 |
| Total Capitalization | $114,085,000 | $38,513,000 | $118,498,000 | $126,259,000 |
| Additional Paid In Capital | $2,362,252,000 | $2,129,207,000 | $2,084,916,000 | $1,998,314,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $0 | $1,934,000 | $1,818,000 | $1,818,000 |
| Long Term Capital Lease Obligation | $3,980,000 | $4,546,000 | $5,895,000 | $6,992,000 |
| Current Deferred Revenue | $517,000 | $589,000 | $509,000 | $25,000 |
| Current Capital Lease Obligation | $1,136,000 | $956,000 | $1,202,000 | $1,209,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $10,199,000 | $8,417,000 | $8,250,000 | $6,377,000 |
| Current Accrued Expenses | $13,469,000 | $8,025,000 | $11,298,000 | $23,747,000 |
| Investments And Advances | $2,511,000 | $0 | - | $0 |
| Available For Sale Securities | $2,511,000 | - | - | - |
| Goodwill | $15,232,000 | $19,139,000 | $26,612,000 | $36,923,000 |
| Net PPE | $18,363,000 | $18,799,000 | $14,129,000 | $15,292,000 |
| Accumulated Depreciation | $-23,823,000 | $-22,871,000 | $-24,283,000 | $-23,439,000 |
| Gross PPE | $42,186,000 | $41,670,000 | $38,412,000 | $38,731,000 |
| Leases | $11,934,000 | $4,478,000 | $4,380,000 | $4,333,000 |
| Construction In Progress | $278,000 | $9,019,000 | $1,577,000 | $531,000 |
| Other Properties | $24,123,000 | $21,830,000 | $25,673,000 | $26,092,000 |
| Machinery Furniture Equipment | $3,058,000 | $3,550,000 | $3,989,000 | $5,019,000 |
| Buildings And Improvements | $2,629,000 | $2,629,000 | $2,629,000 | $2,592,000 |
| Land And Improvements | $164,000 | $164,000 | $164,000 | $164,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $172,000 | $0 | - | - |
| Work In Process | $9,265,000 | $0 | - | - |
| Raw Materials | $144,000 | $0 | - | $15,000 |
| Other Short Term Investments | $67,624,000 | $68,393,000 | $55,277,000 | $51,092,000 |
| Treasury Shares Number | - | - | $7,479,431 | - |
| Dueto Related Parties Current | - | - | - | $0 |
| Other Inventories | - | - | - | $272,000 |
| Duefrom Related Parties Current | - | - | - | $19,000 |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-89,826,000 | $-76,757,000 | $-68,466,000 | $-69,969,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-87,831,000 | $-68,173,000 | $-66,930,000 | $-65,045,000 |
| Cash Flow From Continuing Operating Activities | $-87,831,000 | $-68,173,000 | $-66,930,000 | $-65,045,000 |
| Operating Gains Losses | $139,537,000 | $2,913,000 | $-132,000 | $-1,402,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,995,000 | $-8,584,000 | $-1,536,000 | $-4,924,000 |
| Investing Cash Flow | $-1,535,000 | $-20,714,000 | $-3,087,000 | $226,417,000 |
| Cash Flow From Continuing Investing Activities | $-1,535,000 | $-20,714,000 | $-3,087,000 | $64,111,000 |
| Cash From Discontinued Investing Activities | - | $0 | $0 | $162,306,000 |
| Net Other Investing Changes | - | $60,000 | $98,000 | $594,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-2,196,000 | $0 | $0 | - |
| Financing Cash Flow | $90,048,000 | $110,583,000 | $29,589,000 | $-155,292,000 |
| Cash Flow From Continuing Financing Activities | $90,048,000 | $110,583,000 | $29,589,000 | $-155,292,000 |
| Net Other Financing Charges | $-1,776,000 | - | - | $-588,000 |
| Net Preferred Stock Issuance | $-537,000 | $79,000,000 | $0 | $0 |
| Net Common Stock Issuance | $-1,659,000 | $31,237,000 | $72,808,000 | $0 |
| Issuance Of Capital Stock | - | $110,237,000 | $72,808,000 | $0 |
| Preferred Stock Issuance | - | $79,000,000 | $0 | $0 |
| Common Stock Issuance | - | $31,237,000 | $72,808,000 | $0 |
| Other | ||||
| Repayment Of Debt | $0 | $0 | $-43,219,000 | $-155,293,000 |
| Issuance Of Debt | $92,818,000 | $0 | $0 | $0 |
| Interest Paid Supplemental Data | $3,510,000 | $7,000 | $1,171,000 | $8,535,000 |
| Income Tax Paid Supplemental Data | $3,000 | $4,000 | $21,000 | $0 |
| End Cash Position | $30,234,000 | $29,517,000 | $7,848,000 | $48,596,000 |
| Beginning Cash Position | $29,517,000 | $7,848,000 | $48,596,000 | $43,343,000 |
| Effect Of Exchange Rate Changes | $35,000 | $-27,000 | $-320,000 | $-827,000 |
| Changes In Cash | $682,000 | $21,696,000 | $-40,428,000 | $6,080,000 |
| Proceeds From Stock Option Exercised | $1,202,000 | $346,000 | $0 | $1,000 |
| Preferred Stock Payments | $-537,000 | - | - | - |
| Common Stock Payments | $-1,659,000 | $0 | $0 | - |
| Net Issuance Payments Of Debt | $92,818,000 | $0 | $-43,219,000 | $-155,293,000 |
| Net Long Term Debt Issuance | $92,818,000 | $0 | $-43,219,000 | $-155,293,000 |
| Long Term Debt Payments | $0 | $0 | $-43,219,000 | $-155,293,000 |
| Long Term Debt Issuance | $92,818,000 | $0 | $0 | - |
| Net Investment Purchase And Sale | $460,000 | $-12,190,000 | $-1,649,000 | $68,441,000 |
| Sale Of Investment | $208,466,000 | $175,016,000 | $183,377,000 | $68,441,000 |
| Purchase Of Investment | $-208,006,000 | $-187,206,000 | $-185,026,000 | $0 |
| Net PPE Purchase And Sale | $-1,995,000 | $-8,584,000 | $-1,536,000 | $-4,924,000 |
| Purchase Of PPE | $-1,995,000 | $-8,584,000 | $-1,536,000 | $-4,924,000 |
| Change In Working Capital | $7,361,000 | $4,523,000 | $17,071,000 | $-35,699,000 |
| Change In Other Working Capital | $4,656,000 | $3,341,000 | $5,711,000 | $-23,433,000 |
| Change In Other Current Liabilities | $125,000 | $-55,000 | $-107,000 | $-144,000 |
| Change In Other Current Assets | $-556,000 | $120,000 | $129,000 | $-101,000 |
| Change In Payables And Accrued Expense | $15,637,000 | $-278,000 | $-1,639,000 | $-1,138,000 |
| Change In Accrued Expense | $6,869,000 | $-1,827,000 | $782,000 | $-1,517,000 |
| Change In Payable | $8,768,000 | $1,549,000 | $-2,421,000 | $379,000 |
| Change In Account Payable | $8,768,000 | $1,549,000 | $-2,421,000 | $379,000 |
| Change In Prepaid Assets | $-93,000 | $981,000 | $748,000 | $2,630,000 |
| Change In Inventory | $-9,209,000 | $0 | $0 | $2,341,000 |
| Change In Receivables | $-3,199,000 | $414,000 | $12,229,000 | $-13,513,000 |
| Changes In Account Receivables | $-2,990,000 | $-24,000 | $76,000 | $-2,175,000 |
| Other Non Cash Items | $146,000 | $-1,017,000 | $-13,068,000 | $-79,978,000 |
| Stock Based Compensation | $10,866,000 | $9,471,000 | $9,888,000 | $10,206,000 |
| Asset Impairment Charge | $3,907,000 | $40,324,000 | $10,835,000 | $1,120,000 |
| Amortization Of Securities | $-2,205,000 | $-883,000 | $-1,809,000 | $832,000 |
| Deferred Tax | $0 | $-1,795,000 | $-479,000 | $-150,000 |
| Deferred Income Tax | $0 | $-1,795,000 | $-479,000 | $-150,000 |
| Depreciation Amortization Depletion | $3,199,000 | $4,526,000 | $6,668,000 | $10,765,000 |
| Depreciation And Amortization | $3,199,000 | $4,526,000 | $6,668,000 | $10,765,000 |
| Amortization Cash Flow | $1,273,000 | $3,059,000 | $4,848,000 | - |
| Amortization Of Intangibles | $1,273,000 | $3,059,000 | $4,848,000 | - |
| Depreciation | $1,926,000 | $1,467,000 | $1,820,000 | - |
| Gain Loss On Investment Securities | $139,523,000 | - | - | - |
| Net Foreign Currency Exchange Gain Loss | $0 | $2,915,000 | $0 | $0 |
| Net Income From Continuing Operations | $-250,642,000 | $-126,235,000 | $-95,904,000 | $28,317,000 |
| Provisionand Write Offof Assets | - | $0 | $0 | $944,000 |
| Earnings Losses From Equity Investments | - | $0 | $0 | $-862,000 |
| Net Short Term Debt Issuance | - | - | - | $0 |
| Short Term Debt Payments | - | - | - | $0 |
| Short Term Debt Issuance | - | - | - | $0 |
| Unrealized Gain Loss On Investment Securities | - | - | - | $0 |
| Net Business Purchase And Sale | - | - | - | - |
| Sale Of Business | - | - | - | - |
| Purchase Of Business | - | - | - | - |
Fetched: 2026-06-22